American BioMed To Recommence Trial For Peripheral Atherectomy Catheter
This article was originally published in The Gray Sheet
Executive Summary
American BioMed plans to submit an investigational device exemption in the next 90 days for use of its OmniCath peripheral atherectomy catheter for treatment of hemodialysis arteriovenous (A-V) fistula restenosis.